Agilent Technologies Completes Large-Scale Expansion of Nucleic Acid Manufacturing Capacity
News May 08, 2009
Agilent Technologies Inc. has announced that a major expansion of its Nucleic Acids Solutions Division (NASD) is complete, enabling the company to manufacture several hundred kilograms of therapeutic oligonucleotides per year. This production capacity allows Agilent to meet customers’ supply needs from preclinical and clinical studies through commercial launch, the company says.
NASD now offers a full range of manufacturing capacities for flexible production from grams to hundreds of kilograms of oligonucleotide active pharmaceutical ingredients (APIs). This is the second manufacturing expansion of the Boulder, Colo., facility since Agilent purchased the business in 2006, and involves the addition of large scale nucleic acid synthesis, purification and drying capacity.
“We now have the ability to meet our customers’ growing needs with facilities, equipment and expertise across a broad range of nucleic acid APIs,” said James Powell, NASD general manager.
Agilent’s capacity expansion features the addition of a 1 mol synthesizer capable of producing kilo quantities of API per synthesis batch. Equivalent downstream processing including chromatography, ultrafiltration and lyophilization has also been installed. Corresponding infrastructure and reaction vessels were added for custom conjugation chemistries and duplex annealing of siRNAs.
The DNA Shuffle: Barcoding Trick is Boost to RNA-SeqNews
SPLiT-seq is a new technology that can separate thousands of cells using innovative barcoding technology.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018